Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line

NCT04764487 is registered in ClinicalTrials.gov with Weprom as lead sponsor.

NCT NCT04764487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04764487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line
Lead sponsor
Weprom
Phase
Phase 3
Overall status
Unknown status
Start date
June 7, 2021
Completion date
June 15, 2025
Enrollment
178 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma metastatic